Table 1.
Patient demographics
| Characteristics | N (%) |
|---|---|
| Age (years) | |
| Median (range) | 63 (39–79) |
| Sex | |
| Male | 12 (44.4%) |
| Female | 15 (55.6%) |
| Smoking history | |
| Never | 24 (88.9%) |
| Former or current | 3 (11.1%) |
| Tumor stage | |
| IV | 27 (100%) |
| ECOG PS | |
| 0 | 4 (14.8%) |
| 1 | 10 (37.0%) |
| 2 | 12 (44.5%) |
| 3 | 1 (3.7%) |
| Histology | |
| Adenocarcinoma | 23 (85.2%) |
| Squamous cell carcinoma | 3 (11.1%) |
| Large cell carcinoma | 1 (3.7%) |
| EGFR mutation status | |
| Sensitive mutation | 23 (85.2%) |
| Not detected | 4 (14.8%) |
| Line of apatinib plus icotinib treatment | |
| Second-line | 14 (51.9%) |
| Third- or later-line | 13 (48.1%) |
| Time of icotinib monotherapy failure | |
| ≤6 months | 11 (40.8%) |
| >6 months | 16 (59.2%) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor.